Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Inclusion Criteria: 1. Age ≥18; 2. ECOG is 0-1; 3. Non-small cell lung cancer confirmed by histology; EGFR、ALK and ROS1 negative; 4. The presence of brain metastases as determined by imaging, with unlimited numbers, the intracranial lesions had a maximum diameter of ≥ 0.5cm，allowing the presence of clinical symptoms of brain metastases; 5. According to RECIST 1.1, there is at least one measurable extracranial and intracranial target lesion each; 6. Sign informed consent and agree to collect the clinical efficacy and information of the patient. Exclusion Criteria: 1. Immunotherapeutic contraindications (including long-term use of hormones, history of radiation pneumonia, etc.) 2. Active autoimmune diseases (e.g. vitiligo, psoriasis, hypothyroidism requiring hormone replacement therapy, etc.) 3. Patients with active hepatitis B or C, HIV, active tuberculosis, etc.; 4. Active infections requiring antimicrobial therapy (e.g. antimicrobial, antiviral, antifungal); 5. History of known allogeneic organ transplantation and history of in vivo hematopoietic stem cell transplantation; 6. Patients with interstitial lung disease or previous history of interstitial pneumonia; 7. Having a history of substance abuse and unable to abstain from it or having mental disorders; 8. who have participated in other clinical trials of antitumor drugs within 4 weeks before entering the group; 9. Having used PD-1/PD-L1 and other immunotherapy drugs before entering the group; 10. previous or concurrent with other untreated malignancies, except for cured basal cell carcinoma of the skin, carcinoma of the cervix in situ and superficial bladder cancer; 11. (a) Pregnant or lactating women; those with fertility who are unwilling or unable to take effective contraception; 12. The researchers judged other situations that might affect the conduct of clinical studies and the determination of their findings.